…Introduction Patients with systemic sclerosis (Scleroderma; SSc) are characterised by profound vasculopathy a…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 223 of 2459…ohort.Abstract P.054 Figure 1Overlapping autoantibodies in 2143 systemic sclerosis participants according to anti-NOR-90 autoantibody status…
…d a higher atherosclerotic burden affecting likewise VEDOSS and SSc, implying an early macrovascular damage in the disease course. …
…Introduction Systemic sclerosis (SSc) is a rare autoimmune disease characterized by inflammation and …
…cular risk in rheumatic diseases, that has primarily focused on rheumatoid arthritis (RA). FDA provided a definition of major cardiac adverse event …
…ave devised a novel patient reported outcome (PRO) measure: the Systemic Sclerosis Impact of Digital Ulcer (‘SSiDU’) questionnaire to capture the …
…Introduction Systemic sclerosis, a complex autoimmune disease, is primarily characterized by fi…
…ed so was discontinued.Other medications tried were colchicine, hydroxychloroquine, IV-Ig, and cyclosporine, tocilizumab and abatacept with subopt…
…e symptoms in people with complex medical conditions, including scleroderma. These patient-reported outcomes highlight the feasibility and …
…ematically performed in this cohort.Results Anti-POLR3-positive Johns Hopkins patients had an increased risk of CAS (SIR 2.31, 95% CI 1.59-3.…